19298-14-7

Basic information

• Product Name: 2-(2-Hydroxyethyl)-p-phenylenediamine
• Synonyms: 2-(2-Hydroxyethyl)-p-phenylenediamine;4-(2-HydroxyethylaMino)aniline
• CAS NO: 19298-14-7
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.1937
• Mol File: 19298-14-7.mol

Chemical Properties

• Boiling Point: 360.771 °C at 760 mmHg
• Flash Point: 171.988 °C
• Appearance: /
• Density: 1.216 g/cm³
• CAS DataBase Reference: 2-(2-Hydroxyethyl)-p-phenylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Hydroxyethyl)-p-phenylenediamine(19298-14-7)
• EPA Substance Registry System: 2-(2-Hydroxyethyl)-p-phenylenediamine(19298-14-7)

Safety Data

• Hazardous Substances Data: 19298-14-7(Hazardous Substances Data)

Usage

Uses

Used in Cosmetic Industry:
2-(2-Hydroxyethyl)-p-phenylenediamine is used as a colorant for its ability to impart color to hair and textile products, enhancing their visual appeal and providing a wide range of shades.
2-(2-Hydroxyethyl)-p-phenylenediamine is used as an antioxidant to prevent the oxidation of other ingredients in cosmetic products, thereby extending their shelf life and maintaining their quality.
Used in Hair Dye Industry:
2-(2-Hydroxyethyl)-p-phenylenediamine is used as a hair dye ingredient for its ability to penetrate hair shafts and react with hair proteins, resulting in a permanent color change.
Used in Textile Dye Industry:
2-(2-Hydroxyethyl)-p-phenylenediamine is used as a textile dye ingredient for its ability to bind with fabric fibers, providing long-lasting coloration and resistance to fading.
However, due to the potential health risks associated with 2-(2-Hydroxyethyl)-p-phenylenediamine, such as skin irritation and allergic reactions, its use in cosmetic products is regulated in some countries. Consumers should be aware of its presence in products and use them with caution to minimize potential adverse effects.

Upstream product

• 1965-54-4 N-(2-hydroxyethyl)-4-nitroaniline 
• 141-43-5 ethanolamine 
• 350-46-9 4-Fluoronitrobenzene 
• 890051-96-4 N-(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)phenylene-1,4-diamine 
• 96-49-1 [1,3]-dioxolan-2-one 
• 106-50-3 1,4-phenylenediamine 

Downstream Products

• 959153-96-9 5-chloro-N-(2-{4-[(2-hydroxyethyl)amino]phenyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)thiophene-2-carboxamide 
• 1151893-81-0 2-{2-[1-(5-chlorothiophen-2-yl)-N-{4-[(5S)-5-{[(5-chlorothiophen-2-yl)formamido]methyl}-2-oxo-1,3-oxazolidin-3-yl]phenyl}formamido]ethoxy}acetic acid 
• 1807455-76-0 C₂₅H₂₄Cl₂N₄O₆S₂ 
• 1414781-20-6 2-(4-(4-(cyclopentylamino)-5-nitropyrimidin-2-ylamino)phenylamino)ethanol 

Relevant articles and documents

VEGFR TYROSINE KINASE INHIBITORS

Novel compounds, their prodrugs, and the pharmaceutically acceptable salts as pharmaceutical compositions containing such compounds useful in treating certain diseases modulated by the inhibition of vascular endothelial growth factors (VEGFs) receptor tyrosine kinases are provided. In particular, compounds and compositions and the methods for the prophylaxis, management and treatment of cancers through the inhibition of VEGF receptor tyrosine kinases are provided.

Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations

This paper describe the structural optimization of a hit compound, N 2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine- 2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure-activity relationship studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N 8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.

Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof

The invention relates to novel isoindolin-1-one, isoindolin-3-one and isoindoline-1,3-dione derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

Synthesis of β-amino alcohols from aromatic amines and alkylene carbonates using Na-Y zeolite catalyst

A simple, efficient, and environmentally benign methodology for the synthesis of β-amino alcohols from aromatic amines and alkylene carbonates in the presence of the highly active and reusable solid base catalyst Na-Y zeolite is demonstrated. Georg Thieme Verlag Stuttgart.

4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS

The present invention provides 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula I These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.

Benzenesulfonamide-derivatives and their use as medicaments

Compounds of formula (I), pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, wherein: Ring X is phenyl or a six membered heteroaryl ring containing one or two ring nitrogens where said nitrogens are optionally oxidised to form the N